Tags

Type your tag names separated by a space and hit enter

Efficacy and safety of two or more dexamethasone intravitreal implant injections for treatment of macular edema related to retinal vein occlusion (Shasta study).
Retina. 2014 Feb; 34(2):342-51.R

Abstract

PURPOSE

To evaluate the efficacy, safety, and reinjection interval of dexamethasone intravitreal implant (DEX implant) in branch retinal vein occlusion and central retinal vein occlusion patients receiving ≥ 2 DEX implant treatments.

METHODS

Multicenter (26-site), retrospective chart review study. Data were collected from baseline (at first DEX implant) through 3 months to 6 months after last DEX implant.

RESULTS

Patients (n = 289) received 2 to 9 (mean, 3.2) DEX implants as monotherapy (29.1% of patients) or with adjunctive treatments/procedures. Mean duration of macular edema before first DEX implant was 18.4 months. Mean reinjection interval was 5.6 months. Mean peak change in best-corrected visual acuity from baseline through 4 weeks to 20 weeks after final DEX implant was +1.0 line (P < 0.001). Best-corrected visual acuity and central retinal thickness improved significantly from baseline after each of the first 6 DEX implant injections (P ≤ 0.037); 59.7% of branch retinal vein occlusion and 66.7% of central retinal vein occlusion patients achieved ≥ 2-line best-corrected visual acuity improvement. Intraocular pressure increase (≥ 10 mmHg) occurred in 32.6% of patients; 29.1% used intraocular pressure-lowering medication to treat increases associated with DEX implant. Only 1.7% of patients required incisional glaucoma surgery.

CONCLUSION

Retinal vein occlusion patients treated with multiple DEX implant injections, either alone or combined with other therapies, had improved central retinal thickness and visual acuity with each subsequent injection. No new safety concerns developed with multiple implants.

Authors+Show Affiliations

*Associated Retinal Consultants, Novi, Michigan; †Department of Ophthalmology, Oakland University, William Beaumont Hospital School of Medicine, Rochester, Michigan; ‡Medical Center Ophthalmology Associates, San Antonio, Texas; §Illinois Retina Center, Springfield, Illinois; ¶Retina Northwest PC, Portland, Oregon; **Associated Retinal Consultants, Traverse City, Michigan; ††Retina-Vitreous Center, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, New Jersey; ‡‡Allergan, Inc, Irvine, California.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial, Phase IV
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23846381

Citation

Capone, Antonio, et al. "Efficacy and Safety of Two or More Dexamethasone Intravitreal Implant Injections for Treatment of Macular Edema Related to Retinal Vein Occlusion (Shasta Study)." Retina (Philadelphia, Pa.), vol. 34, no. 2, 2014, pp. 342-51.
Capone A, Singer MA, Dodwell DG, et al. Efficacy and safety of two or more dexamethasone intravitreal implant injections for treatment of macular edema related to retinal vein occlusion (Shasta study). Retina. 2014;34(2):342-51.
Capone, A., Singer, M. A., Dodwell, D. G., Dreyer, R. F., Oh, K. T., Roth, D. B., Walt, J. G., Scott, L. C., & Hollander, D. A. (2014). Efficacy and safety of two or more dexamethasone intravitreal implant injections for treatment of macular edema related to retinal vein occlusion (Shasta study). Retina (Philadelphia, Pa.), 34(2), 342-51. https://doi.org/10.1097/IAE.0b013e318297f842
Capone A, et al. Efficacy and Safety of Two or More Dexamethasone Intravitreal Implant Injections for Treatment of Macular Edema Related to Retinal Vein Occlusion (Shasta Study). Retina. 2014;34(2):342-51. PubMed PMID: 23846381.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy and safety of two or more dexamethasone intravitreal implant injections for treatment of macular edema related to retinal vein occlusion (Shasta study). AU - Capone,Antonio,Jr AU - Singer,Michael A, AU - Dodwell,David G, AU - Dreyer,Richard F, AU - Oh,Kean T, AU - Roth,Daniel B, AU - Walt,John G, AU - Scott,Lanita C, AU - Hollander,David A, PY - 2013/7/13/entrez PY - 2013/7/13/pubmed PY - 2014/7/17/medline SP - 342 EP - 51 JF - Retina (Philadelphia, Pa.) JO - Retina VL - 34 IS - 2 N2 - PURPOSE: To evaluate the efficacy, safety, and reinjection interval of dexamethasone intravitreal implant (DEX implant) in branch retinal vein occlusion and central retinal vein occlusion patients receiving ≥ 2 DEX implant treatments. METHODS: Multicenter (26-site), retrospective chart review study. Data were collected from baseline (at first DEX implant) through 3 months to 6 months after last DEX implant. RESULTS: Patients (n = 289) received 2 to 9 (mean, 3.2) DEX implants as monotherapy (29.1% of patients) or with adjunctive treatments/procedures. Mean duration of macular edema before first DEX implant was 18.4 months. Mean reinjection interval was 5.6 months. Mean peak change in best-corrected visual acuity from baseline through 4 weeks to 20 weeks after final DEX implant was +1.0 line (P < 0.001). Best-corrected visual acuity and central retinal thickness improved significantly from baseline after each of the first 6 DEX implant injections (P ≤ 0.037); 59.7% of branch retinal vein occlusion and 66.7% of central retinal vein occlusion patients achieved ≥ 2-line best-corrected visual acuity improvement. Intraocular pressure increase (≥ 10 mmHg) occurred in 32.6% of patients; 29.1% used intraocular pressure-lowering medication to treat increases associated with DEX implant. Only 1.7% of patients required incisional glaucoma surgery. CONCLUSION: Retinal vein occlusion patients treated with multiple DEX implant injections, either alone or combined with other therapies, had improved central retinal thickness and visual acuity with each subsequent injection. No new safety concerns developed with multiple implants. SN - 1539-2864 UR - https://www.unboundmedicine.com/medline/citation/23846381/Efficacy_and_safety_of_two_or_more_dexamethasone_intravitreal_implant_injections_for_treatment_of_macular_edema_related_to_retinal_vein_occlusion__Shasta_study__ L2 - https://doi.org/10.1097/IAE.0b013e318297f842 DB - PRIME DP - Unbound Medicine ER -